HELLO.
I'M Mark W Schwartz
Director at Targazyme
Dr. Mark W. Schwarz - Faculty Member at San Jose State University
About Mark W Schwartz
An accomplished biotechnology executive, Mark W. Schwartz, PhD, has substantial experience in business development and operations. When he served as the president and CEO of Bayhill Therapeutics, Inc., from 2004 to 2009, the company developed a number of unique, new gene therapies. One of these, the DNA vaccine platform BHT-DNA, was designed for the treatment of several autoimmune diseases, and Mark W. Schwartz obtained regulatory approval for clinical trials in 16 countries and raised more than $100 million in venture capital and nondilutive capital to bring it to market. Dr. Schwartz previously held key management positions with Galena Biopharma, Inc., and Apthera, Inc.
Mark W. Schwartz holds a PhD in biochemistry from Arizona State University and a bachelor of arts in chemistry from Grinnell College. In his free time, he pursues hobbies that include reading, playing ice hockey, and wakeboarding. He draws on his business experience to serve as a board member for the biotechnology program at San Jose State University and as a guest lecturer with the Donald L. Wilson Program in Entrepreneurship and Leadership at Grinnell College.Education
Arizona State University
PhD Aug 1, 1978 - Nov 1, 1983
Chemistry/Biochemistry
Grinnell College
BA Aug 1, 1973 - Jun 1, 1977
Chemistry
- The BlogRead more...A former director at Galena Biopharma, Mark W. Schwartz has since moved on to the position of...Read more...Dr. Mark W. Schwartz serves as executive director at Targazyme, a biopharmaceutical company in...June 23, 2018Read more...The holder of a PhD in chemistry from Arizona State University (ASU), Mark W. Schwartz is a...
Natasha Kingsley © 2017